This case suggests that, in unresectable stage III pulmonary squamous cell carcinoma, a combined strategy of limited-fraction LRT plus VMAT with concurrent chemotherapy, together with on-treatment adaptive replanning, can achieve favorable short-term efficacy and acceptable toxicity while maintaining OAR doses within constraints. This approach provides a practical reference for individualized radiotherapy with complex target volumes.
Zhou et al. (Wed,) studied this question.